A recent study has now compared the overall cost of TMS treatment with standard pharmacological interventions for the disorder (i.e. antidepressant medications), taking into consideration direct financial cost as well as “Quality Adjusted Life Years” (QALYs). Given current costs of treatment, the findings show that TMS is more cost-effective over the life-span of adults with MDD, compared to antidepressant medication trials.
Studies show that a patient is more liekly to sustain benefit of TMS treatment, or achieve complete remission, when this technique is combined with a form of ‘talk-therapy’ (Donse et al. 2017)
However, in many countries TMS is usually only recommended for patients after having failed several antidepressant medication trials. These findings therefore support TMS being a recommended earlier in a patient’s treatment journey, given it is found to be more cost effective than standard pharmacological interventions for MDD. (Voigt, Carpenter & Leuchter (2017)